Europe
BioSpace scanned the WARN (Worker Adjustment and Retraining Notification) notices across the country and compiled a small list of recent layoffs across the industry.
Their work has helped in the development of new medications to fight anemia, cancer and many other diseases.
The drug is called BOS172722 and it forces cancer cells to multiply faster, which would seem to be counterintuitive. However, this faster cell division causes more fatal errors in the cells.
The Board of Directors of Promore Pharma AB has resolved to carry out a new share issue with preferential rights for the Company’s existing shareholders of a total of SEK 75 million excluding transaction costs.
Hutchison China MediTech Limited has initiated an international Phase I/Ib study of HMPL-523, its novel spleen tyrosine kinase inhibitor, in patients with relapsed or refractory lymphoma.
Target number of clinical sites reached, including leading hospitals and geriatric centers in the US and Europe Patient enrollment expected to complete in mid-2020
Company also announces participation in BioJapan 2019, one of Asia’s largest partnering events for the global biotechnology industry, October 9-11, 2019 in Pacifico Yokohama
It was another busy week for clinical trials. Here’s a look.
The approval was based on data from the Phase III GRECO clinical trial and the Phase I AMES trial.
Lonza has partnered with Nephron Pharmaceuticals Corporation to implement Lonza’s next-generation MODA-ES™ EBR Platform to streamline manufacturing compliance reporting
PRESS RELEASES